In Vitro and In Vivo Antagonism of a G Protein-Coupled Receptor (S1P3) with a Novel Blocking Monoclonal Antibody

Background: S1P 3 is a lipid-activated G protein-couple receptor (GPCR) that has been implicated in the pathological processes of a number of diseases, including sepsis and cancer. Currently, there are no available high-affinity, subtypeselective drug compounds that can block activation of S1P3. We have developed a monoclonal antibody (7H9) that specifically recognizes S1P3 and acts as a functional antagonist. Methodology/Principal Findings: Specific binding of 7H9 was demonstrated by immunocytochemistry using cells that over-express individual members of the S1P receptor family. We show, in vitro, that 7H9 can inhibit the activation of S1P3mediated cellular processes, including arrestin translocation, receptor internalization, adenylate cyclase inhibiton, and calcium mobilization. We also demonstrate that 7H9 blocks activation of S1P3 in vivo, 1) by preventing lethality due to systemic inflammation, and 2) by altering the progression of breast tumor xenografts. Conclusions/Significance: We have developed the first-reported monoclonal antibody that selectively recognizes a lipidactivated GPCR and blocks functional activity. In addition to serving as a lead drug compound for the treatment of sepsi

CONTENT CURATION FOR INFORMATION LITERACY AND KNOWLEDGE MANAGEMENT IN IMMUNOLOGY USING SCOOP.IT

International audienceReferences The topics, curated almost daily, gather more than 25K highly selected scoops over the last 40 months, compared to 200K or 400K results found with Pubmed or Google Scholar respectively on similar topics. Scoops are dealing with published (classical or OPEN) and grey literature (blogs, websites, social networks, press releases…) allowing rapid access to recently published relevant information. The audience is steadily increasing, with over 175K views, and more than 70K visitors for the most successful topic entitled Immunology (http://www.scoop.it/t/immunology), covering basic immunology (5,8K scoops, >101 K views) since 2011. Immunological basic sciences, Biotechnologies, BioTherapies are covered by the following topics besides Immunology: From Flow Cytometry to Cytomics, http://www.scoop.it/t/from-flow-cytometry-to-cytomics (3,9K scoops, >18,5 K views) Immunology and Biotherapies, http://www.scoop.it/t/immunology-and-biotherapies (5,7K scoops, >14K views) Mucosal Immunity http://www.scoop.it/t/mucosal-immunity (2,9K s, 7.5K v) History of Immunology. http://www.scoop.it/t/history-of-immunology Immuno-Pathology is covered through topics: Autoimmunity, http://www.scoop.it/t/autoimmunity (2,5K s, 6K v) Allergy (and clinical immunology), http://www.scoop.it/t/allergy-and-clinical-immunology Rheumatology

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II

BACKGROUND. The purpose of the present study was to assess the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy male volunteers. METHODS AND RESULTS. In the first study (single-dose study), eight volunteers were included in a 2-day protocol repeated four times at 1-week intervals. In each phase, a different dose of drug (2.5, 5, 10, 20, or 40 mg) or placebo was given. The peak systolic blood pressure response to a test-dose of angiotensin I was determined serially before and after oral administration of DuP 753 by continuously monitoring finger blood pressure using a photoplethysmographic method. DuP 753 reduced the systolic blood pressure response to angiotensin I in a dose-dependent fashion. Three, 6, and 13 hours after the 40-mg dose, blood pressure response decreased to 31 +/- 5%, 37 +/- 6%, and 45 +/- 3% of the control values (mean +/- SEM, n = 7), respectively. In the second study, 29 volunteers were treated for 8 days with either a placebo or DuP 753 (5, 10, 20, or 40 mg p.o. q.d.) and challenged on the first, fourth, and eighth days with bolus injections of angiotensin II. Again, the inhibitory effect on the systolic blood pressure response to angiotensin II was clearly dose dependent. Six hours after 40 mg DuP 753, the systolic blood pressure response to the test-dose of angiotensin II was reduced to 37 +/- 7%, 40 +/- 4%, and 38 +/- 6% of baseline values (mean +/- SEM, n = 6) on days 1, 4, and 8, respectively. With this latter dose, there was still a blocking effect detectable 24 hours after the drug. Similar to angiotensin converting enzyme and renin inhibitors, DuP 753 induced a dose-dependent increase in plasma renin that was more pronounced on the eighth than on the first day of drug administration. In these normal volunteers, no consistent clinically significant side effects were observed. There was no evidence for an agonist effect. CONCLUSIONS. DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men